. Author manuscript; available in PMC: 2009 Oct 14.

Published in final edited form as: Cancer Gene Ther. 2008 Apr 11;15(7):413–448. doi: 10.1038/cgt.2008.15

Table 5.

ERBB3 in mammary cancers and cancer cells

	References
Evidence implicating ERBB3 in mammary cancer development
ERBB3 activation in mammary tumors in transgenic mice	188–190
Increased ERBB3 mRNA or protein in many primary human breast cancers	184,186,191,192,195,199
Clear role in survival and cell growth in many human breast cancer cell lines	143,211–214,221,228–231
Upregulation as a mode of escape from mammary tumor cell suppression by tyrosine kinase inhibitors, via pAkt feedback	127,139
Ambiguities
Variable relationship of mRNA or protein to clinical prognosis	High ERBB3 favorable or null:¹⁹⁷,¹⁹⁸,²⁰⁰
	High ERBB3 unfavorable:¹⁸⁴,¹⁸⁶, ¹⁹³–¹⁹⁵,²⁰⁰,²⁰¹,²⁰³
Conflicting evidence regarding relationship to estrogen receptor expression	193,200,203
NRG-dependent mammary cell differentiation, apoptosis, or growth suppression	82,184,232,233